Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Neuroticism Associates with Cerebral in Vivo Serotonin Transporter Binding Differently in Males and Females

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Altered Expression Pattern of Clock Genes in a Rat Model of Depression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: [11C]Cimbi-36 is a serotonin 2A receptor agonist positron emission tomography radioligand that has recently been examined in humans. The binding of agonist radioligand is expected to be more sensitive to endogenous neurotransmitter concentrations than antagonist radioligands. In the current study, we compared the effect of serotonin releaser fenfluramine on the binding of [11C]Cimbi-36, [11C]MDL 100907 (a serotonin 2A receptor antagonist radioligand), and [11C]AZ10419369 (a serotonin 1B receptor partial agonist radioligand with established serotonin sensitivity) in the monkey brain.

Methods: Eighteen positron emission tomography measurements, 6 for each radioligand, were performed in 3 rhesus monkeys before or after administration of 5.0 mg/kg fenfluramine. Binding potential values were determined with the simplified reference tissue model using cerebellum as the reference region.

Results: Fenfluramine significantly decreased [11C]Cimbi-36 (26-62%) and [11C]AZ10419369 (35-58%) binding potential values in most regions (P < 0.05). Fenfluramine-induced decreases in [11C]MDL 100907 binding potential were 8% to 30% and statistically significant in 3 regions. Decreases in [11C]Cimbi-36 binding potential were larger than for [11C]AZ10419369 in neocortical and limbic regions (~35%) but smaller in striatum and thalamus (~40%). Decreases in [11C]Cimbi-36 binding potential were 0.9 to 2.8 times larger than for [11C]MDL 100907, and the fraction of serotonin 2A receptor in the high-affinity state was estimated as 54% in the neocortex.

Conclusions: The serotonin sensitivity of serotonin 2A receptor agonist radioligand [11C]Cimbi-36 was higher than for antagonist radioligand [11C]MDL 100907. The serotonin sensitivity of [11C]Cimbi-36 was similar to [11C]AZ10419369, which is one of the most sensitive radioligands. [11C]Cimbi-36 is a promising radioligand to examine serotonin release in the primate brain.

OriginalsprogEngelsk
TidsskriftInternational Journal of Neuropsychopharmacology
Vol/bind20
Udgave nummer9
Sider (fra-til)683-691
Antal sider9
ISSN1461-1457
DOI
StatusUdgivet - 1 sep. 2017

ID: 51787849